Since the activity of AMPK is reduced in obesity, increasing AMPK activity has been suggested as an attractive therapeutic option for obesity-associated metabolic diseases, including NAFLD/NASH8–10,19,20. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.